| Urgent Care Medical Clinic, Pc | |
|
9150 Jewel Lake Rd Ste B Anchorage AK 99502-5337 | |
| (907) 248-8561 | |
| (907) 248-8563 |
| Full Name | Urgent Care Medical Clinic, Pc |
|---|---|
| Speciality | Clinic/Center |
| Location | 9150 Jewel Lake Rd Ste B, Anchorage, Alaska |
| Authorized Official Name and Position | Talmadge Layne Crowe (OWNER/PROVIDER) |
| Authorized Official Contact | 9072488561 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Urgent Care Medical Clinic, Pc 9150 Jewel Lake Rd Ste B Anchorage AK 99502-5337 Ph: (907) 248-8561 | Urgent Care Medical Clinic, Pc 9150 Jewel Lake Rd Ste B Anchorage AK 99502-5337 Ph: (907) 248-8561 |
| NPI Number | 1497781678 |
|---|---|
| Provider Enumeration Date | 06/23/2006 |
| Last Update Date | 10/18/2022 |
| Medicare PECOS PAC ID | 8123918513 |
|---|---|
| Medicare Enrollment ID | O20040318001007 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497781678 | NPI | - | NPPES |
| MDG6361 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | 242636 (Alaska) | Primary |
| Provider Name | Timothy V Samuelson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1821085036 PECOS PAC ID: 4688588486 Enrollment ID: I20031201000485 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
| Provider Name | John R Quimby |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1558470229 PECOS PAC ID: 5799700514 Enrollment ID: I20051011000751 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
| Provider Name | Talmadge Layne Crowe |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1942319611 PECOS PAC ID: 1658261045 Enrollment ID: I20051011000832 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
| Provider Name | Calvin J Billman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1356450027 PECOS PAC ID: 3779508502 Enrollment ID: I20051011000857 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
| Provider Name | Sara L Stout |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1679769814 PECOS PAC ID: 4284787656 Enrollment ID: I20150720003474 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
| Provider Name | Jordin A Thompson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457723827 PECOS PAC ID: 7113220674 Enrollment ID: I20160118000660 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
| Provider Name | Curtis C Harvie |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033550173 PECOS PAC ID: 9335377282 Enrollment ID: I20160901002650 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
| Provider Name | Martha F Rosenstein |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871946780 PECOS PAC ID: 7416243936 Enrollment ID: I20160909001374 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
| Provider Name | Erin B Norton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114439197 PECOS PAC ID: 6103184908 Enrollment ID: I20171228001317 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
| Provider Name | Elise Nancy Bishop |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861129256 PECOS PAC ID: 4981070380 Enrollment ID: I20221025003179 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
| Provider Name | Carlene Ann Mott |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295465797 PECOS PAC ID: 0446622419 Enrollment ID: I20230221002083 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.
› Verified 7 days ago
Alaska Premier Health Alaska Sports Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3300 Arctic Blvd, 101, Anchorage, AK 99503 Phone: 907-561-3488 Fax: 907-562-3488 | |
Alaska Family Care Associates, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4001 Dale Street, Suite 210, Anchorage, AK 99508 Phone: 907-929-5888 Fax: 907-929-5882 | |
Daryl M. Mcclendon, M.d., P.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3851 Piper St, Suite U466, Anchorage, AK 99508 Phone: 907-569-1333 Fax: 907-569-1433 | |
Willow Wellness Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3030 Wendys Way Unit A, Anchorage, AK 99517 Phone: 406-253-7924 | |
Douglas Carter Smith, Md Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 17741 Mountainside Village Dr, Anchorage, AK 99516 Phone: 907-345-0728 Fax: 907-345-0728 | |
Internal Medicine Associates, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2841 Debarr Rd Ste 50, Anchorage, AK 99508 Phone: 907-276-2811 Fax: 907-276-2810 | |
Summit Family Practice Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2741 Debarr Rd, Suite C308, Anchorage, AK 99508 Phone: 907-272-3366 Fax: 907-272-0269 |